1. Home
  2. ZYME vs PPTA Comparison

ZYME vs PPTA Comparison

Compare ZYME & PPTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • PPTA
  • Stock Information
  • Founded
  • ZYME 2003
  • PPTA 2011
  • Country
  • ZYME United States
  • PPTA United States
  • Employees
  • ZYME N/A
  • PPTA N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • PPTA Precious Metals
  • Sector
  • ZYME Health Care
  • PPTA Basic Materials
  • Exchange
  • ZYME Nasdaq
  • PPTA Nasdaq
  • Market Cap
  • ZYME 751.6M
  • PPTA 854.6M
  • IPO Year
  • ZYME 2017
  • PPTA N/A
  • Fundamental
  • Price
  • ZYME $13.23
  • PPTA $12.74
  • Analyst Decision
  • ZYME Buy
  • PPTA Strong Buy
  • Analyst Count
  • ZYME 6
  • PPTA 2
  • Target Price
  • ZYME $18.83
  • PPTA $18.50
  • AVG Volume (30 Days)
  • ZYME 416.1K
  • PPTA 803.6K
  • Earning Date
  • ZYME 10-31-2024
  • PPTA 11-13-2024
  • Dividend Yield
  • ZYME N/A
  • PPTA N/A
  • EPS Growth
  • ZYME N/A
  • PPTA N/A
  • EPS
  • ZYME N/A
  • PPTA N/A
  • Revenue
  • ZYME $62,199,000.00
  • PPTA N/A
  • Revenue This Year
  • ZYME $21.53
  • PPTA N/A
  • Revenue Next Year
  • ZYME N/A
  • PPTA N/A
  • P/E Ratio
  • ZYME N/A
  • PPTA N/A
  • Revenue Growth
  • ZYME N/A
  • PPTA N/A
  • 52 Week Low
  • ZYME $7.97
  • PPTA $2.69
  • 52 Week High
  • ZYME $17.70
  • PPTA $13.18
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 42.19
  • PPTA 64.64
  • Support Level
  • ZYME $12.43
  • PPTA $11.26
  • Resistance Level
  • ZYME $14.10
  • PPTA $12.96
  • Average True Range (ATR)
  • ZYME 0.63
  • PPTA 0.82
  • MACD
  • ZYME -0.10
  • PPTA 0.14
  • Stochastic Oscillator
  • ZYME 26.50
  • PPTA 84.93

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About PPTA Perpetua Resources Corp.

Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.

Share on Social Networks: